Search

Displaying results 5381 - 5390 of 9322 in total
  1. Drug

    Cinalukast

    go.drugbank.com/drugs/DB00587
    Experimental

    Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. … Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.

    Synonyms: 3'-((E)-2-(4-cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid
  2. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication … It inhibits dopamine release and alters the firing of dopaminergic neurons.

  3. Drug

    Xylazine

    go.drugbank.com/drugs/DB11477
    InvestigationalVet approved

    [L42680] The intentional and unintentional use of xylazine is a cause for concern due to its side effects. … vital functions and increase the risk of overdose and death.

  4. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    Human olfactory mucosa-derived mesenchymal stem cells (OM-MSCs) reside in an accessible location of the nasal cavity and have properties of multipotency and high proliferation, which contributes to high … In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps.

  5. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. … Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.

  6. Drug

    Deutarserine

    go.drugbank.com/drugs/DB19057
    Investigational

    Deutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).

  7. Drug

    Revaprazan

    go.drugbank.com/drugs/DB16308
    Investigational

    Revaprazan is under investigation in clinical trial NCT01750437 (Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(nerd)

  8. Drug

    PF-06882961

    go.drugbank.com/drugs/DB16043
    Investigational

    PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).

  9. Drug

    Dirocaftor

    go.drugbank.com/drugs/DB16143
    Investigational

    Dirocaftor is under investigation in clinical trial NCT03251092 (Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis).

  10. Drug

    V590

    go.drugbank.com/drugs/DB16437
    Experimental

    Merck is currently underway to begin Phase I trials for the vaccine through intramuscular administration (NCT04569786). … The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578].